New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed) | RFA DK 21 030

Opportunity Information: Apply for RFA DK 21 030

The New Investigator Gateway Awards for Collaborative T1D Research is an NIH funding opportunity (RFA-DK-21-030) built to strengthen the pipeline of new and early stage investigators working on type 1 diabetes (T1D). It uses the R03 mechanism and is explicitly marked as "Clinical Trial Not Allowed," which means the projects supported under this announcement must stay on the non-clinical-trial side of the NIH definition. In practical terms, the program is aimed at early, innovative, and often preliminary research that can generate key proof-of-concept findings, produce foundational data for future larger applications, and help launch independent research trajectories in T1D.

A defining feature of this program is that it is not just funding for an isolated pilot study; it is designed to place new investigators into the intellectual and collaborative setting of established, large-scale T1D research consortia or collaborative programs. The idea is that awardees conduct their work while being embedded in an active research network that already has shared resources, ongoing projects, experienced investigators, and a culture of collaboration. This structure is meant to accelerate learning and professional development by exposing new investigators to the field's major scientific questions, contemporary methods, shared datasets or platforms where applicable, and the day-to-day reality of team science. At the same time, the consortia benefit by bringing in new perspectives, fresh ideas, and novel approaches that can challenge assumptions or open up new directions.

From an applicant standpoint, the opportunity is broadly available across many organization types that commonly apply for NIH grants. Eligible applicants include public and private institutions of higher education, nonprofits (both 501(c)(3) and non-501(c)(3)), for-profit organizations other than small businesses, small businesses, and multiple levels of government organizations (state, county, city/township, special districts), as well as independent school districts and public housing authorities/Indian housing authorities. It also explicitly welcomes a wide range of mission- or community-oriented entities and institutions that serve populations historically underrepresented in biomedical research ecosystems, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs). Faith-based or community-based organizations and regional organizations are also listed among eligible applicants, along with eligible federal agencies.

The foreign eligibility rules are nuanced and worth stating clearly. Non-domestic (non-U.S.) entities and non-domestic foreign institutions are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are also not eligible to apply. However, "foreign components" as defined by the NIH Grants Policy Statement are allowed. In NIH terms, that typically means the primary awardee must be an eligible domestic applicant, but certain parts of the work can be conducted internationally or involve foreign collaborations when justified and structured according to NIH policy and approvals.

Administratively, this is a discretionary grant opportunity from the National Institutes of Health, listed under the Health and Food/Nutrition/Health activity categories and associated with CFDA number 93.847. The source information provided lists an original closing date of March 20, 2023, a creation date of December 3, 2021, and an award ceiling of $1,000,000 (noting that ceilings can reflect maximums across varying circumstances and do not necessarily represent typical budgets for all R03 awards). The announcement also indicates that expected awards were not specified in the source snippet. Overall, the core purpose is career-building and science-building at the same time: supporting early, high-potential T1D studies while intentionally integrating new investigators into collaborative networks that can strengthen mentorship, expand professional connections, and set up durable collaborations that continue beyond the award period.

• The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
• This funding opportunity was created on 2021-12-03.
• Applicants must submit their applications by 2023-03-20. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DK 21 030

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: